Treatment of multidrug-resistant tuberculosis in Taiwan

Jen Suo, Ming Chih Yu, Chun Nin Lee, Chen Yuan Chiang, Tao Pin Lin

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Eighty-seven patients with multidrug-resistant tuberculosis (MDR-TB) diagnosed between 1988 and 1990 were treated with isoniazid and at least three other effective second-line drugs based on in vitro susceptibility tests. Of these patients, 10% failed to adhere to the regimen and 43% remained sputum positive after 6 months of treatment. Only 47% showed sputum conversion within 6 months of treatment and 12% of them relapsed during the first year of follow-up. From September 1987 to July 1989, 36 patients with MDR-TB were treated with a regimen containing rifabutin, isoniazid and at least three other susceptible drugs. Only 47% achieved a sustained sputum conversion. Four died during treatment due to disease progression. From March 1992 to July 1993, 17 cases of MDR-TB were treated with an ofloxacin-containing anti-TB regimen for 12-24 months. Two failed to adhere to the regimen for more than 1 month during the first 6 months of therapy. Among the remaining 15, 26% failed to achieve sputum conversion, 73% achieved bacterial conversion, 9 within 1 month and the other 2 within 2 months. No significant adverse effect was associated with ofloxacin use. We concluded that ofloxacin is a better choice among the more toxic and less potent second-line drugs, and should be used along with other anti-TB drugs in treating patients with MDR-TB.

Original languageEnglish
Pages (from-to)20-23
Number of pages4
JournalChemotherapy
Volume42
Issue numberSUPPL. 3
Publication statusPublished - Dec 1996
Externally publishedYes

Fingerprint

Multidrug-Resistant Tuberculosis
Sputum
Taiwan
Ofloxacin
Isoniazid
Pharmaceutical Preparations
Rifabutin
Poisons
Therapeutics
Disease Progression

Keywords

  • Fluoroquinolone
  • Multidrug-resistant tuberculosis
  • Ofloxacin

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Suo, J., Yu, M. C., Lee, C. N., Chiang, C. Y., & Lin, T. P. (1996). Treatment of multidrug-resistant tuberculosis in Taiwan. Chemotherapy, 42(SUPPL. 3), 20-23.

Treatment of multidrug-resistant tuberculosis in Taiwan. / Suo, Jen; Yu, Ming Chih; Lee, Chun Nin; Chiang, Chen Yuan; Lin, Tao Pin.

In: Chemotherapy, Vol. 42, No. SUPPL. 3, 12.1996, p. 20-23.

Research output: Contribution to journalArticle

Suo, J, Yu, MC, Lee, CN, Chiang, CY & Lin, TP 1996, 'Treatment of multidrug-resistant tuberculosis in Taiwan', Chemotherapy, vol. 42, no. SUPPL. 3, pp. 20-23.
Suo, Jen ; Yu, Ming Chih ; Lee, Chun Nin ; Chiang, Chen Yuan ; Lin, Tao Pin. / Treatment of multidrug-resistant tuberculosis in Taiwan. In: Chemotherapy. 1996 ; Vol. 42, No. SUPPL. 3. pp. 20-23.
@article{eefee42caefe4d4db8bc3bd18c4eba1c,
title = "Treatment of multidrug-resistant tuberculosis in Taiwan",
abstract = "Eighty-seven patients with multidrug-resistant tuberculosis (MDR-TB) diagnosed between 1988 and 1990 were treated with isoniazid and at least three other effective second-line drugs based on in vitro susceptibility tests. Of these patients, 10{\%} failed to adhere to the regimen and 43{\%} remained sputum positive after 6 months of treatment. Only 47{\%} showed sputum conversion within 6 months of treatment and 12{\%} of them relapsed during the first year of follow-up. From September 1987 to July 1989, 36 patients with MDR-TB were treated with a regimen containing rifabutin, isoniazid and at least three other susceptible drugs. Only 47{\%} achieved a sustained sputum conversion. Four died during treatment due to disease progression. From March 1992 to July 1993, 17 cases of MDR-TB were treated with an ofloxacin-containing anti-TB regimen for 12-24 months. Two failed to adhere to the regimen for more than 1 month during the first 6 months of therapy. Among the remaining 15, 26{\%} failed to achieve sputum conversion, 73{\%} achieved bacterial conversion, 9 within 1 month and the other 2 within 2 months. No significant adverse effect was associated with ofloxacin use. We concluded that ofloxacin is a better choice among the more toxic and less potent second-line drugs, and should be used along with other anti-TB drugs in treating patients with MDR-TB.",
keywords = "Fluoroquinolone, Multidrug-resistant tuberculosis, Ofloxacin",
author = "Jen Suo and Yu, {Ming Chih} and Lee, {Chun Nin} and Chiang, {Chen Yuan} and Lin, {Tao Pin}",
year = "1996",
month = "12",
language = "English",
volume = "42",
pages = "20--23",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Treatment of multidrug-resistant tuberculosis in Taiwan

AU - Suo, Jen

AU - Yu, Ming Chih

AU - Lee, Chun Nin

AU - Chiang, Chen Yuan

AU - Lin, Tao Pin

PY - 1996/12

Y1 - 1996/12

N2 - Eighty-seven patients with multidrug-resistant tuberculosis (MDR-TB) diagnosed between 1988 and 1990 were treated with isoniazid and at least three other effective second-line drugs based on in vitro susceptibility tests. Of these patients, 10% failed to adhere to the regimen and 43% remained sputum positive after 6 months of treatment. Only 47% showed sputum conversion within 6 months of treatment and 12% of them relapsed during the first year of follow-up. From September 1987 to July 1989, 36 patients with MDR-TB were treated with a regimen containing rifabutin, isoniazid and at least three other susceptible drugs. Only 47% achieved a sustained sputum conversion. Four died during treatment due to disease progression. From March 1992 to July 1993, 17 cases of MDR-TB were treated with an ofloxacin-containing anti-TB regimen for 12-24 months. Two failed to adhere to the regimen for more than 1 month during the first 6 months of therapy. Among the remaining 15, 26% failed to achieve sputum conversion, 73% achieved bacterial conversion, 9 within 1 month and the other 2 within 2 months. No significant adverse effect was associated with ofloxacin use. We concluded that ofloxacin is a better choice among the more toxic and less potent second-line drugs, and should be used along with other anti-TB drugs in treating patients with MDR-TB.

AB - Eighty-seven patients with multidrug-resistant tuberculosis (MDR-TB) diagnosed between 1988 and 1990 were treated with isoniazid and at least three other effective second-line drugs based on in vitro susceptibility tests. Of these patients, 10% failed to adhere to the regimen and 43% remained sputum positive after 6 months of treatment. Only 47% showed sputum conversion within 6 months of treatment and 12% of them relapsed during the first year of follow-up. From September 1987 to July 1989, 36 patients with MDR-TB were treated with a regimen containing rifabutin, isoniazid and at least three other susceptible drugs. Only 47% achieved a sustained sputum conversion. Four died during treatment due to disease progression. From March 1992 to July 1993, 17 cases of MDR-TB were treated with an ofloxacin-containing anti-TB regimen for 12-24 months. Two failed to adhere to the regimen for more than 1 month during the first 6 months of therapy. Among the remaining 15, 26% failed to achieve sputum conversion, 73% achieved bacterial conversion, 9 within 1 month and the other 2 within 2 months. No significant adverse effect was associated with ofloxacin use. We concluded that ofloxacin is a better choice among the more toxic and less potent second-line drugs, and should be used along with other anti-TB drugs in treating patients with MDR-TB.

KW - Fluoroquinolone

KW - Multidrug-resistant tuberculosis

KW - Ofloxacin

UR - http://www.scopus.com/inward/record.url?scp=0029855524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029855524&partnerID=8YFLogxK

M3 - Article

C2 - 8980864

AN - SCOPUS:0029855524

VL - 42

SP - 20

EP - 23

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - SUPPL. 3

ER -